High base, weak margins dent Q3 performance Cadila Healthcare (Cadila) reported Q3FY22 results...
Key News Standard Chartered, IATA tie up forh payment platform for airline industry Global ...
Bharti Airtel Buy Bharti Airtel Ltd @ 7534.00-7542.00 CMP 753...
Cadila Healthcare is currently trading at Rs. 412.00, up by 5.20 points or 1.28% from its previou...
Cadila Healthcare is currently trading at Rs. 469.35, up by 1.80 points or 0.38% from its previou...
Cadila Healthcare is currently trading at Rs. 468.00, up by 5.35 points or 1.16% from its previou...
Steady Q2; US growth remains a concern Cadila Healthcare (Cadila) reported Q2FY22 results broa...
Cadila Healthcare is currently trading at Rs. 497.15, up by 2.55 points or 0.52% from its previou...
Indian steady in Q2 but US slowdown persists… About the stock: Cadila is a leading phar...
Indian shines but US slowdown persists… About the stock: Cadila is a leading pharma com...
Vaccine approval adds a new dimension to the domestic business * CDH has received emergency us...
Steady Q1; US remains under pressure Cadila Healthcare (Cadila) reported Q1FY22 performance be...
Buy Cadila Healthcare Ltd For Target Rs.670 Domestic Formulations drive earnings Comprehens...
Below is quote on Cadila Healthcare Limited results by Mr. Yash Gup...
Below are Quote on Cadila healthcare business sale by Mr. Yash Gupta, Equity ...
Strong domestic growth mostly offset by US decline… Q4 revenues grew 2.5% YoY to | 3847...
Margin supported by lower R&D Cadila Healthcare (Cadila) reported Q4FY21 performance large...
Saroglitazar’s PBC Phase 2 data: Good efficacy, average safety * Saroglitazar’s Ph...
India sales/operating leverage drives earnings R&D on track for COVID-19 vaccine/niche pro...
Strategic reprioritizing led to the divestment of the Animal Health business * CDH has entered...
R&D on track for COVID 19vaccine/Niche Product Development Cadila Healthcare Ltd (CDH...
Below are Quote on Cadila healthcare up by 0.75% on positive development of USFDA approval&n...
Modest operational beat; downgrade to Hold * Cadila’s revenue was in line with our estim...
Solid result; Outlook remains intact Cadila Healthcare is India’s leading vertically int...
Cadila Healthcare is currently trading at Rs. 629.30, up by 9.95 points or 1.61% from its previou...
Below are Quote on Cadila Healthcare - 4QFY21 by Mr. Yash Gupta E...
Below are Quote on Cadila Healthcare to sell medicine for black fungus by Mr.&nb...
Cadila Healthcare is currently trading at Rs. 626.25, up by 3.80 points or 0.61% from its previou...
Divestment of animal health business to be earnings neutral * Cadila has entered into an agree...
Below are Quote on Update on Cadila Healthcare by Mr. Yash Gupta ...
Axis Bank Buy Axis Bank Ltd @ 704.50-705.50 CMP 706.50&nbs...
Observation * CADILAHC for the past 4 weeks has been forming a higher high higher low pattern....
Cadila Healthcare is currently trading at Rs. 579.00, up by 7.80 points or 1.37% from its previou...
‘Virafin’ approval bodes well to tackle rising COVID cases * Cadila Healthcare (CD...
Cadila Healthcare Buy Cadila Healthcare Ltd @ 527.00-529.00. CMP...
Cadila Healthcare is currently trading at Rs. 522.00, up by 7.45 points or 1.45% from its previou...
Cadila Healthcare is currently trading at Rs. 474.10, up by 12.85 points or 2.79% from its previo...
Technical Stock Pick Observations: * Cadila Healthcare is in an intermediate uptrend since ...
Cadila Healthcare is currently trading at Rs. 448.15, up by 8.30 points or 1.89% from its previou...
Revlimid settlement: directionally positive * Cadila announced the settlement of Revlimid pat...
Revlimid settlement enhances business visibility CDH – Fifth company to settle with inn...
Cadila Healthcare is currently trading at Rs. 433.00, up by 1.95 points or 0.45% from its previou...
Steady quarter; Vaccine is the key trigger Cadila Healthcare (Cadila) reported Q3FY21 perform...
Steady quarter; innovation pipeline build-up continues * We reiterate Buy on Cadila with an un...
Cadila Healthcare is currently trading at Rs. 440.55, up by 2.75 points or 0.63% from its previou...
* We reiterate Buy on Cadila with an unchanged TP of Rs655 post a steady Q3. We also maintain our...
India, EMs drive earnings NCEs / Complex Generics / Vaccines progressing as expected * Ca...
Below are Quote On Cadila Healthcare 3QFY21 By Mr. Yash Gupta Equity Research...